DHRS11
Dehydrogenase/reductase SDR family member 11
Protein Summary
Catalyzes the conversion of the 17-keto group of estrone, 4- and 5-androstenes and 5-alpha-androstanes into their 17-beta-hydroxyl metabolites and the conversion of the 3-keto group of 3-, 3,17- and 3,20- diketosteroids into their 3-hydroxyl metabolites. Exhibits reductive 3-beta-hydroxysteroid dehydrogenase activity toward 5-beta-androstanes, 5-beta-pregnanes, 4-pregnenes and bile acids. May also reduce endogenous and exogenous alpha-dicarbonyl compounds and xenobiotic alicyclic ketones.
- ENST00000611337
- ENSP00000477603
- ENSG00000278535
- ENST00000618403
- ENSP00000482704
- ENST00000621143
- ENSP00000483747
- ENSG00000275397
- ENST00000631686
- ENSP00000488610
- SDR24C1
- ARPG836
- SDR24C1
- spDHRS11
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.84 | ||
histone modification site profile | 0.68 | ||
cell type or tissue | 0.63 | ||
tissue | 0.59 | ||
protein domain | 0.58 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 209.61 (req: < 5)
Gene RIFs: 2 (req: <= 3)
Antibodies: 176 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 209.61 (req: >= 5)
Gene RIFs: 2 (req: > 3)
Antibodies: 176 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0